CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Rezdiffra is now the first and only approved therapy in the European Union (EU) for the treatment of MASH.
Related Questions
What pricing and reimbursement strategy will Madrigal pursue in Europe, and how might that impact profit margins?
How does Rezdiffra's market positioning compare to existing and pipeline MASH therapies in terms of competitive advantage and market share potential?
How will the EU approval of Rezdiffra affect Madrigal's revenue forecasts and valuation?